Immunization with a novel HIV-1-Tat multiple-peptide conjugate induces effective immune response in mice

被引:11
作者
Boykins, RA
Ardans, JA
Wahl, LM
Lal, RB
Yamada, KM
Dhawan, S [1 ]
机构
[1] US FDA, Ctr Biol Evaluat & Res, Mol Virol Lab, Immunopathogenesis Sect, Bethesda, MD 20892 USA
[2] Ctr Dis Control & Prevent, Immunopathogenesis Lab, Atlanta, GA 30333 USA
[3] Natl Inst Dent & Craniofacial Res, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA
[4] Natl Inst Dent & Craniofacial Res, Immunopathol Sect, NIH, Bethesda, MD 20892 USA
[5] US FDA, Ctr Biol Evaluat & Res, Lab Parasit Biol & Biochem, Bethesda, MD 20892 USA
关键词
monocytes; macrophages; HIV-1-Tat; HIV; AIDS; pathogenesis; vaccine;
D O I
10.1016/S0196-9781(00)00334-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We report here a novel, highly immunogenic synthetic, multiple-peptide conjugate comprising functional domains Tat(21-40) and Tat(53-68) from HIV-I group M plus Tat(9-20) from HIV-I group O of the HIV-Tat protein (HIV-1-Tat-MPC). Vaccination of mice with HIV-I-Tat-MPC induced an effective immune response to all three functional domains. The anti-HTV-1-Tat-MPC antibodies efficiently inhibited Tar-induced viral activation in monocytes infected with HIV(Ba-L) as well as with various clinical HIV-l isolates, and reduced Tat-mediated cytopathicity in infected cells by 60-75%. Our results indicate that anti-HIV-l-Tat-MPC antibodies inhibit viral pathogenesis, possibly by blocking functional determinants of Tar and disrupting autocrine and paracrine actions of secreted Tat protein. This epitope-specific, synthetic Tat construct may, therefore, provide a subunit AIDS vaccine candidate for inducing an effective immunoprophylaxis response to reduce progression of HIV infection. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1839 / 1847
页数:9
相关论文
共 38 条
[1]   Identification of a novel domain of HIV Tat involved in monocyte chemotaxis [J].
Albini, A ;
Benelli, R ;
Giunciuglio, D ;
Cai, T ;
Mariani, G ;
Ferrini, S ;
Noonan, DM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (26) :15895-15900
[2]  
ALBINI A, 1999, J HUMAN VIROL, V2, P179
[3]   Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease [J].
Berger, EA ;
Murphy, PM ;
Farber, JM .
ANNUAL REVIEW OF IMMUNOLOGY, 1999, 17 :657-700
[4]   PROTECTION OF CHIMPANZEES FROM INFECTION BY HIV-1 AFTER VACCINATION WITH RECOMBINANT GLYCOPROTEIN GP120 BUT NOT GP160 [J].
BERMAN, PW ;
GREGORY, TJ ;
RIDDLE, L ;
NAKAMURA, GR ;
CHAMPE, MA ;
PORTER, JP ;
WURM, FM ;
HERSHBERG, RD ;
COBB, EK ;
EICHBERG, JW .
NATURE, 1990, 345 (6276) :622-625
[5]  
Boykins RA, 1999, J IMMUNOL, V163, P15
[6]   Synthesis and construction of a novel multiple peptide conjugate system: strategy for a subunit vaccine design [J].
Boykins, RA ;
Joshi, M ;
Syin, C ;
Dhawan, S ;
Nakhasi, H .
PEPTIDES, 2000, 21 (01) :9-17
[7]   Why do we not have an HIV vaccine and how can we make one? [J].
Burton, DR ;
Moore, JP .
NATURE MEDICINE, 1998, 4 (05) :495-498
[8]   Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine [J].
Cafaro, A ;
Caputo, A ;
Fracasso, C ;
Maggiorella, MT ;
Goletti, D ;
Baroncelli, S ;
Pace, M ;
Sernicola, L ;
Koanga-Mogtomo, ML ;
Betti, M ;
Borsetti, A ;
Belli, R ;
Åkerblom, L ;
Corrias, F ;
Buttò, S ;
Heeney, J ;
Verani, P ;
Titti, F ;
Ensoli, B .
NATURE MEDICINE, 1999, 5 (06) :643-650
[9]  
Caselli E, 1999, J IMMUNOL, V162, P5631
[10]   HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region [J].
Chang, HC ;
Samaniego, F ;
Nair, BC ;
Buonaguro, L ;
Ensoli, B .
AIDS, 1997, 11 (12) :1421-1431